Prospera Financial Services Inc Cuts Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Prospera Financial Services Inc reduced its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 25.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 41,674 shares of the company’s stock after selling 13,975 shares during the quarter. Prospera Financial Services Inc’s holdings in Teva Pharmaceutical Industries were worth $751,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Coronation Fund Managers Ltd. purchased a new position in Teva Pharmaceutical Industries in the second quarter worth $1,334,000. Point72 Asset Management L.P. grew its holdings in Teva Pharmaceutical Industries by 38.0% in the second quarter. Point72 Asset Management L.P. now owns 1,319,217 shares of the company’s stock worth $21,437,000 after purchasing an additional 363,217 shares during the last quarter. Lighthouse Investment Partners LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the second quarter worth $6,825,000. Ritholtz Wealth Management lifted its stake in shares of Teva Pharmaceutical Industries by 269.5% during the third quarter. Ritholtz Wealth Management now owns 41,643 shares of the company’s stock worth $750,000 after buying an additional 30,374 shares during the period. Finally, Diversify Wealth Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the third quarter worth $640,000. 54.05% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. UBS Group lifted their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Barclays lifted their price objective on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 23rd. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, October 21st. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $19.67.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, EVP Christine Fox sold 19,388 shares of the company’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the transaction, the executive vice president now owns 44,104 shares in the company, valued at approximately $744,034.48. This represents a 30.54 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Trading Up 0.2 %

Shares of Teva Pharmaceutical Industries stock opened at $17.12 on Friday. The firm has a 50-day simple moving average of $17.70 and a two-hundred day simple moving average of $17.30. The company has a market cap of $19.40 billion, a P/E ratio of -20.14, a price-to-earnings-growth ratio of 1.31 and a beta of 0.87. Teva Pharmaceutical Industries Limited has a fifty-two week low of $9.35 and a fifty-two week high of $19.31. The company has a debt-to-equity ratio of 2.57, a quick ratio of 0.61 and a current ratio of 0.89.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.